Khaberni - Official data in Britain revealed that more than 170 deaths have been linked to weight-loss injection procedures since 2007, among them the deaths of two young people in their twenties, which has triggered an increasing wave of concern about the safety of these widely used treatments in recent years.
According to "The Sun" newspaper, the British drug regulatory authorities received 173 reports of deaths related to slimming injections that mimic the GLP-1 hormone since 2007, including medicines such as Ozempic, Mounjaro, and Wegovy.
Interestingly, 52 death cases have been reported to the British Medicines and Healthcare products Regulatory Agency since only 2024.
Inappropriate Use
This comes at a time when more people are turning to drugs like Ozempic, Wegovy, and Mounjaro for weight loss, and concerns are growing about their "inappropriate" use for this purpose.
The reported deaths do not confirm that they were caused by the drug, but merely raise suspicions that this could be the case.
One-third of the deaths were in middle age, with 8 in their thirties, 15 in their forties, and 37 in their fifties.
Factors Leading to Complications
Tam Fry, head of the National Obesity Forum in Britain, said: "If you take these medications without needing them, and break the rules, you expose yourself to the risk of serious complications, or death."
The chemical found in Ozempic and Wegovy - semaglutide - was linked to 31 deaths, and 38 cases were associated with tirzepatide, the active ingredient in Mounjaro.
The British Ministry of Health emphasized: "These licensed medications should only be used under medical supervision by qualified individuals."
Meanwhile, the manufacturing companies of Ozempic, Wegovy, and Mounjaro confirmed that patient safety is their top priority.
